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A 72-year-old woman was diagnosed with uveal melanoma, peritoneal mesothelioma and a primary biliary tract
adenocarcinoma. She had a strong family history of mesothelioma as well as other malignancies including renal
cell carcinoma. The recently described BAP1 hereditary cancer predisposition syndrome was suspected, but
immunohistochemical labeling was not conclusive. Genetic testing confirmed a novel and unusual germline
mutation in the ubiquitin hydrolase domain of the BAP1 gene (p.Tyr173Cys) and the patient was diagnosed with the
BAP1 hereditary cancer predisposition syndrome. This case demonstrates the importance of clinically recognizing this rare
syndrome and its manifestations, some which are still being characterized. It also highlights the importance of genetic
testing in cases where there is a high clinical suspicion, even when screening tests, such as immunohistochemistry, in this
case, are inconclusive. The diagnosis of a germline BAP1 mutation may have important implications for both the patient
and their families with regards to further genetic testing and active surveillance programs. Further research is needed to
fully understand the extent and clinical implications of this rare cancer syndrome.
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A number of rare cancers, in particular mesothelioma
and uveal melanoma have been shown to occur together,
being noted as early as the 1970s. Furthermore there
have been cases of strong familial clustering of malignant
mesothelioma, often with limited asbestos exposure, a
known carcinogen recognized as causing mesothelioma.
Genetic studies of these families subsequently lead to the
discovery of germline mutations in BAP1 and the recogni-
tion of a new cancer predisposition syndrome. At present
this syndrome has been shown to predispose to the
development of uveal melanoma, malignant mesotheli-
oma, cutaneous melanoma and renal cell carcinoma, but
has also been implicated in the development of other ma-
lignancies. Here we report the first case of this new cancer
syndrome in Australia, leading to the development of 3
distinct malignancies.* Correspondence: sonja.klebe@health.sa.gov.au
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A 72-year-old, previously well, woman was found to have
left ocular uveal melanoma on ophthalmology review
(Fig. 1). She had previously been noted to have ‘freckles’
on her left retina. At the time of diagnosis the patient was
asymptomatic, suffered no visual impairment and declined
further investigation, radiotherapy or enucleation. A one-
year follow up showed growth of the uveal melanoma with
staging undertaken prior to intended radiotherapy. An
abdominal CT scan demonstrated a lesion within seg-
ments 4 and 7 of her liver (Fig. 1). A Further PET scan
showed a focal area of FDG avidity within segment 4 but
no increased FDG uptake in liver segment 7,
A diagnostic laparoscopy was performed for the liver
lesions of unknown origin. Intraoperatively, no free
intraperitoneal fluid was seen but numerous peritoneal
nodules were noted on the diaphragmatic and peritoneal
surfaces, particularly in the right upper quadrant. There
was no obvious omental disease. These peritoneal
nodules along with the liver lesion were biopsied. The
liver biopsy showed focally necrotic poorly differentiated
adenocarcinoma. Immunohistochemical labeling was in
keeping with cholangiocarcinoma and in the absence oficle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Imaging of patient with germline BAP1 mutation. a. Retinal
examination revealed a melanocytic tumor with irregular margins
involving the majority of the retina. b. CT of the abdomen prior to
surgery identified a 32 mm lobulated lesion in segment 4B of the
liver as indicated by the arrow
Fig. 2 Pedigree of the patient’s family with a BAP1 germline mutation.
Black Squares indicate a diagnosis of malignant mesothelioma. Arrow
indicates the presence of BAP1 mutation as determined by
sequencing studies. Two of the patient’s children passed away with
renal cell carcinoma (RCC) and acute lymphocytic leukaemia (ALL)
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gastrointestinal tract the lesion was considered to likely
represent a primary intrahepatic cholangiocarcinoma.
The lesion did not label for any immunohistochemical
markers for melanoma. The peritoneal biopsy showed
nodular proliferations of mesothelial cells with infiltra-
tion into the submesothelial adipose tissue indicative of
malignant mesothelioma of epithelial type. Immunohis-
tochemistry was positive for mesothelial markers and
negative for carcinoma markers.
The patient’s father and brother had both died of
malignant mesothelioma (Fig. 2) having had occupational
exposure to asbestos. The patient herself had no occupa-
tional exposure to asbestos but may have had ongoing
household exposure since the 1970s. Her past medical
history was unremarkable besides beta thalassemia minor
and a previous hysterectomy for benign disease. The
patient was of Greek descent. She was a non-smoker andonly occasionally drank alcohol. The patient had four
children, and two of these had passed away with renal cell
carcinoma and acute lymphocytic leukaemia at ages 41
and 17 respectively (Fig. 2).
Elective surgical resection was deemed appropriate for
the patient’s primary liver mass. A CT prior to resection
demonstrated no change in the liver lesion and no
evidence of extrahepatic spread. Intraoperatively, a firm
porta hepatic node was identified with frozen sectioning
confirming metastatic adenocarcinoma. Fine needle
aspiration of the segment 7 also showed adenocarcinoma
and in view of positive intra- and extrahepatic disease
the liver resection was abandoned. A strip of peritoneum
was also removed which again demonstrated malignant
mesothelioma.
In light of her uveal melanoma and malignant
mesothelioma, combined with her family history of
mesothelioma it was suspected that the patient might
have BAP1 hereditary cancer predisposition syndrome.
Testing for BAP1 mutations by immunohistochemistry
showed loss of nuclear BAP1 labeling in the primary
biliary tract adenocarcinoma, but nuclear labeling for
BAP1 was retained in the malignant mesothelioma
(Fig. 3). No biopsies were taken from the uveal melan-
oma. Germline DNA sequencing was performed and
revealed the patient to carry a germline missense mutation
in the catalytic domain (g.52441252A >G, p.Tyr173Cys)
located in exon 7 of the BAP1 gene (Fig. 4). This mutation
is predicted to generate a non-functional full-length
protein, due to impairment of its ubiquitin hydrolase
activity.
Fig. 3 Histological findings of patient with BAP1 germline mutation a. Liver biopsy demonstrating focally necrotic poorly differentiated
intrahepatic adenocarcinoma (Hemosiderin and Eosin, original magnification 250×). b. Immunohistochemical labeling for BAP1 protein in the
cholangiocarcinoma, showing loss of nuclear staining. (Santa Cruz BAP1 monoclonal antibody (sc-28383) 1: 200. Dako dual system detection,
original magnification 400×) c. Peritoneal biopsy demonstrating malignant mesothelioma of epithelial type with invasion into the submesothelial
adipose tissue. (Hemosiderin and Eosin, original magnification 250×). d. Immunohistochemical labeling for BAP1 for peritoneal biopsy showing
retained BAP1 nuclear staining in malignant peritoneal mesothelioma (Tissue preparation s above, original magnification 400×)
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an enlarging liver mass, development of new liver lesions
and increasing portacaval lymph nodes. No other distant
sites of metastasis where identified on CT. The patient
become symptomatic 23 months after the diagnosis of
cholangiocarcinoma and mesothelioma and was com-
menced on palliative chemotherapy. She passed away
31 months after diagnosis of cholangiocarcinoma and
mesothelioma due to progression of her intraabdominal
malignancies.
Discussion
BAP1 hereditary cancer predisposition syndrome was
first described in 2011 based on investigations of two
American families [1]. It is a syndrome that describes a
predisposition to the development of several malig-
nancies, in particular uveal melanoma and malignant
mesothelioma as well as cutaneous melanomas, basal
cell carcinomas and renal cell carcinoma [2-7]. Other
cancers have been reported in families suffering germline
mutations but no direct correlations have yet been
established. In a review of 76 patients with a BAP1
germline mutation, 53 patients had developed at least
one malignancy with 13 developing at least two. Those
who had not yet developed a malignancy were all aged
less than 55 [8]. This study highlights the strong link
between germline BAP1 mutations and carcinogenesis.
Here, we reported a case involving an individual with agermline BAP1 mutation who was diagnosed with 3
distinct malignancies in short succession, an event that
appears uncommon even for individuals carrying a
germline BAP1 mutation.
BAP1 (BRCA1-associated protein 1) is a nuclear pro-
tein encoded by the tumour suppressor gene located on
chromosome 3p21.1 [9]. It is a deubiquitinating enzyme,
usually part of a protein complex, and has been impli-
cated in a number of different cellular processes includ-
ing chromatin remodeling, cell cycle progression, cell
differentiation and DNA damage responses [4]. The un-
derstanding of BAP1’s role in cellular processes and sub-
sequent carcinogenesis has increased in recent years
however the function of BAP1 is still being fully charac-
terized, in particular its contribution to carcinogenesis.
Both germline and somatic mutations have been impli-
cated in tumour progression [1, 3, 9]. BAP1 mutations
may result in proteins that lack the nuclear localization
sequence, or may affect its deubiquitinase activity [1, 4, 9].
It is not fully known why germline mutations may
predispose to the development of certain cancers over
others; most likely cell-type specific functions as well as
gene-environment interactions play an important role.
The BAP1 germline alteration identified in our patient
was a missense mutation at the active site of its ubiquitin
hydrolase domain. Similar missense mutations were found
in uveal melanoma (p.Ser172Arg) [10] and pleural bi-
phasic mesothelioma (p.Tyr173Ser) tissue [11]. While the
Fig. 4 Germline BAP1 missense mutation found in this patient. Germline DNA was extracted from the patient’s blood and analysed by Sanger
sequencing. DNA amplification and sequencing were performed as previously described (Forward primer: GGAGTTGGCCAAGGCCCATAATAGC; reverse
primer: CCTGGATACTCTCTGTCCCTCCCAAAG) [1]. Electropherogram shows BAP1 missense mutation (g.52441252A > G) within exon 7. This mutation
produces an amino-acid sequence switch from tyrosine to cysteine in the ubiquitin hydrolase domain (UCH), and indicated by the diagram
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role of the deubiquitinating.activity of BAP1 in its tumour
suppressor activities have been well established [12, 8] The
tumor suppressor function of BAP1 has been shown to
require its nuclear localization. Therefore absence of BAP1
nuclear staining and/or presence of cytoplasmic BAP1 in-
dicate the presence of an abnormal BAP1 protein. Both
N-terminus BAP1 mutations and C-terminus mutations
lead to lack of BAP1 nuclear labeling due to either lack of
the nuclear localization signal, or to lack of deubiquitinase
activity, as autodeubiquition is required for nuclear trans-
port of BAP1 protein [13]. This has been confirmed in a
comprehensive study showing that all BAP1 abnormalities
found in mesothelioma to date are always associated with
absence of BAP1 nuclear staining and/or presence of cyto-
plasmic BAP1 staining [14].
The complete loss of BAP1 nuclear staining observed in
our primary biliary tract adenocarcinoma is likely due to
LOH at somatic level, while the mesothelioma tissue
seems to have preserved the other BAP1 allele. One could
argue that the fact that mesothelioma developed even inabsence of LOH further confirms the deleteriousness of
the Tyr 173 mutation. Definitive sequencing was not per-
formed on tumour samples, which were largely exhausted
by diagnostic tests. Loss of nuclear BAP1 staining on im-
munohistochemistry was thought to be an accessible and
reliable test of BAP1 mutations, including germline [15, 8]
and has been used for prognostication in mesothelioma
[16, 17]. However the presence of retained nuclear staining
in this case highlights the need for clinician awareness
of BAP1 germline mutations and for definitive germline
genetic testing.
With regards to specific cancers, germline BAP1 muta-
tions have been shown to play a role in a small number
(3-4 %) of uveal melanomas [18, 19]. Uveal melanoma is
a rare ocular cancer with variable outcome, depending
on molecular and clinical characteristics [20]. BAP1
mutations have been implicated in metastatic ability. A
germline mutation was found in 4 out of 50 metastatic
uveal melanomas and was not identified in a further 50
non-metastatic tumours [18]. Sporadic BAP1 mutations
have also been found in 84 % of metastasizing uveal
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sporadic appears to lead to a more aggressive tumour
phenotype in uveal melanoma.
Malignant mesothelioma is another rare cancer that
has been associated with BAP1 germline mutations [4].
It is an aggressive cancer with limited treatment
options often due to late diagnosis. Both germline and
sporadic BAP1 mutations has been shown to play a role
in malignant mesothelioma. BAP1 appears to be sporadic-
ally mutated in a significant portion ~60 % of malignant
mesotheliomas [11, 1, 14, 9]. Germline mutations
make up much smaller proportion of cancers. A recent
study compared the clinical characteristics of 23 meso-
theliomas that occurred in carriers of germline BAP1
mutations to 10,556 sporadic mesotheliomas [21].
These patients tended to have a family history of malig-
nant mesothelioma with limited asbestos exposure. Tu-
mors that occur in a setting of germline BAP1
mutations are much less aggressive than their somatic
counterparts and are associated with a significant im-
proved mean survival of 5 years compared to 1 year
with sporadic malignant mesothelioma [21]. This im-
proved survival is observed in the patient reported here.
Loss of nuclear labeling for BAP1 in the absence of
known germline mutations has been associated with a
less dramatic improvement in prognosis [17, 16]. Germ-
line mutations also had a higher incidence of peritoneal
disease (as in our patient) where in sporadic tumours
pleural disease predominates. The recent discovery of
BAP1 involvement has given much needed insight into
the pathogenesis of mesothelioma and in particular has
added valuable prognostic information [16, 17].
Germline BAP1 mutations have cutaneous manifesta-
tions that include basal cell carcinomas, malignant
melanoma and the recently described melanocytic-
BAP1 mutated atypical intradermal tumour (MBAIT)
[2, 8, 6, 5, 7]. MBAITs are pink to tan benign skin
tumours around 0.2 – 1 cm in diameter that macro-
scopically resembles dermal nevi but are clinically,
histologically, and genetically distinct. They have been
shown to have high levels of mutated BRAF which can
distinguish them from benign Spitz naevi [15]. They
can appear as early as the second decade with an indi-
vidual developing multiple lesions over their lifetime.
They appear clinically stable with a low malignant po-
tential but there are reports of progression to malignant
melanoma. The number of cutaneous melanoma is still
low in these families despite significant number of
MBAITs. Bi-allelic loss of BAP1 in itself along with a
BRAF mutation is not sufficient for melanoma formation
[2]. It has been suggested that MBAITs may be used to
screen individuals for germline BAP1 mutations; 19 out of
35 individuals with a BAP1 mutation were found to have
one or more lesion [4]. Furthermore, MBAITs occurearlier than other associated malignancies, allowing for
identification of at risk individuals, genetic testing and
implementation of surveillance protocols.
Renal cell carcinoma is the most recent tumour asso-
ciated with BAP1 germline mutations. The majority of
renal cancers are sporadic however a small proportion
(2-4 %) is familial, the majority of these due to Von
Hippel Lindau syndrome [22]. A much smaller compo-
nent can be attributed to germline BAP1 mutations
[3, 23]. It should be noted that our patient’s son died of
renal cell carcinoma. Sporadic BAP1 mutations have
also been associated with a more aggressive form of
cancer [24] however it appears germline mutations may
have different consequences [3]. Further research is
needed to understand the contributing and prognostic
role of BAP1 in renal cell carcinoma.
Other cancers including meningioma, lung, ovarian,
pancreatic and breast cancers have been found in fam-
ilies that harbor BAP1 germline mutations [4]. However
it is unclear whether germline BAP1 mutations directly
predispose to the development of these tumours.
Our patient was diagnosed with a primary biliary
tract cancer. There are reports of individuals with
BAP1 mutations developing primary biliary tract can-
cers but no definitive predisposition has been attributed
[4, 21]. Somatic BAP1 mutations are relatively frequent
in cholangiocarcinoma [25-28]. Our own immuno-
histochemistry showed complete loss of BAP1 nuclear
staining in the primary biliary tract adenocarcinoma.
This indicates that secondary sporadic mutations had
occurred in the adenocarcinoma, resulting in loss of
protein translocation (Fig. 3). Further epidemiological
studies are needed to confirm whether primary biliary
tract tumours, contribute to the spectrum of BAP1
hereditary cancer predisposition syndrome.
The recent discovery of this rare cancer predisposition
syndrome has a number of clinical implications. Firstly, it
is important to identify these patients and their families
through genetic testing. It would be advisable to perform
genetic testing on patients diagnosed with uveal melan-
oma and mesothelioma, those with mesothelioma who
have a strong family history of the disease and as well as
those found to have MBAITs. The indication of offering
BAP1 genetic testing for other familial cancer associations
is less clear, considering the rarity of this syndrome. Those
who are confirmed to carry a BAP1 mutation will then
need appropriate genetic counseling for themselves and
their families. Some authors advocate affected family
members should undergo annual total skin checks for
MBAITs as well as ocular examination [8]. As the full
extent of this syndrome is not yet known it is unclear what
the appropriate surveillance programs should be. Early
detection and management of malignant mesothelioma
and other related malignancies may improve survival.
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BAP1 mutations have been described in some US and
European families with a very high incidence of cancer
and they are transmitted in a Mendelian fashion (i.e.,
about 50 % of offspring inherit the mutation). So far all
of the family members that inherited this mutation
have developed one and often several cancers by age 65
(18). Characteristically, when malignancies occur in a
setting of germline BAP1 mutations they are less ag-
gressive and patients live significantly longer compared
to patients with the same types of tumors occurring in
a sporadic setting [21]. Here we describe the first
Australian family affected by the BAP1 cancer
syndrome. Our findings reveal that this cancer syn-
drome is ubiquitous and it is not restricted to the US
and Europe. Clearly identification of these patients is
critical to provide them correct medical advice and
genetic counseling.
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